Data Presented at the 2025 TCT Conference from the Real-World Global Paradise System Registry Show a Significant and Meaningful BP Reduction at 6 Months, and
Palo Alto, Calif. – October 28, 2025 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced that
First Medical Device Approved in Japan for the Treatment of Hypertension PALO ALTO, CA – AUGUST 25, 2025 – Recor Medical, Inc. (“Recor”), a wholly owned subsidiary
Palo Alto, Calif. – August 15, 2025 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), appreciate
Palo Alto, Calif. – July 10, 2025 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their
World Hypertension Day’s Focus on High Blood Pressure Awareness, Management and Control Highlights Importance of New Therapies, like Ultrasound Renal Denervation Palo Alto, CA,
Palo Alto, Calif. – January 13, 2025 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that
The Paradise Ultrasound Renal Denervation (uRDN) system becomes the first and only ultrasound-based renal denervation (RDN) therapy to be granted a distinct category and device
The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and
Statement from the AHA in support of Renal Denervation as a hypertension therapy option provides reinforcement that the treatment can have a meaningful positive impact
